SCHEMBL27095258

SCHEMBL27095258

CC(C)(C)OC(=O)N1CC2(COc3cc(C(=O)O)c(CO)cc3O2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 7/20 0.38
▸ GPR183 P32249 1/20 0.38
▸ SCD5 Q86SK9 2/20 0.33
▸ PARP1 P09874 1/20 0.32
▸ RORC P51449 1/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ JAK1 P23458 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32
▸ CHRM2 P08172 1/20 0.31
▸ CHRM4 P08173 1/20 0.31
▸ CHRM1 P11229 1/20 0.31
▸ CHRM3 P20309 1/20 0.31
▸ MAPT P10636 2/20 0.31
▸ IDO1 P14902 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ USP2 O75604 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30746323 1.00 GPR119 (0.38) GPR119GPR183SCD5PARP1RORC
SCHEMBL31024662 0.78 EED (0.36) GPR119GPR183SCD5HRH3MAPT
SCHEMBL31024668 0.78 EED (0.36) GPR119GPR183SCD5HRH3MAPT
SCHEMBL25345030 0.78 EED (0.36) GPR119GPR183SCD5HRH3MAPT
SCHEMBL30746089 0.74 MTOR (0.37) GPR119GPR183SCD5HRH3CHRM2
SCHEMBL27095388 0.74 MTOR (0.37) GPR119GPR183SCD5HRH3CHRM2
SCHEMBL31024669 0.74 GPR119 (0.40) GPR119GPR183SCD5HRH3IDO1
SCHEMBL25343228 0.72 GPR119 (0.36) GPR119GPR183SCD5HRH3USP2
SCHEMBL30746295 0.71 GPR183 (0.35) GPR119GPR183SCD5PARP1HRH3
SCHEMBL27095341 0.71 GPR183 (0.35) GPR119GPR183SCD5PARP1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENT OF THE UNIV OF MICHIGAN (US) 2026-01-29 — — US disclosed
US-20240059704-A1 Cereblon Ligands and Uses Thereof ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. 2024-02-22 — — US disclosed
WO-2024015412-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059704-A1 Cereblon Ligands and Uses Thereof CRBN, CDR2, CHLSN GPR119 983/4885GPR183 761/4885SCD5 4832/4885
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, ESRRB GPR119 602/4885GPR183 298/4885SCD5 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback